Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes. The CONNECT study evaluated the current-generation G7 continuous glucose monitor (CGM) in people with type 2 diabetes not using insulin. It compared this population to a routine care control group using self-monitoring of blood glucose. Researchers shared […]
Drug-Device Combinations
Abbott studies reinforce DKA opportunity following dual sensor milestone
Abbott (NYSE:ABT) today announced new clinical data highlighting the importance of managing diabetic ketoacidosis (DKA). The medtech giant shared findings from multiple studies at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans that demonstrate sharp increases in DKA-related hospitalizations across all age groups with type 1 and type 2 diabetes nationwide. Abbott […]
Insulet data backs Omnipod 6, fully closed-loop AID systems
Insulet (Nasdaq:PODD) today announced new clinical findings for its next-generation Omnipod 6 and fully closed-loop algorithm. The company shared results from its STRIVE pivotal trial and EVOLUTION 3 feasibility study. Investigators presented the outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Findings demonstrated meaningful improvements in glucose control for people […]
Tidepool data highlights automated insulin delivery algorithm enhancements, women’s health initiative
Tidepool has new clinical insights and research initiatives related to diabetes management and automated insulin delivery (AID) technology. Palo Alto, California-based Tidepool is a non-profit diabetes data management group. It developed the FDA-cleared Tidepool Loop, a “do-it-yourself” (DIY) AID system. The hybrid, closed-loop AID app has compatibility with multiple insulin pumps and continuous glucose monitors. […]
MannKind shares more data backing inhaled insulin
MannKind (Nasdaq:MNKD) today announced new clinical findings for its Afrezza inhaled insulin powder and Furoscix furosemide injection. The company shared outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. MannKind’s Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to […]
Glooko launches EHR integration for insulin pumps
Glooko announced today that it launched its Insulin Pump Settings Electronic Health Record (EHR) integration capability. Palo Alto, California-based Glooko says the first-of-its-kind capability within its latest software release visualizes critical insulin pump configuration data directly into the clinical workflow. The company says that visibility of pump settings provides essential clinical context for clinics caring […]
Tandem wins CE mark for automated insulin delivery in type 2 diabetes, pregnancy
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received expanded CE mark for its automated insulin delivery (AID) systems. San Diego-based Tandem can now bring its Control-IQ-powered AID systems — the flagship t:slim X2 and miniature Mobi — to European adults with type 2 diabetes and those with type 1 diabetes during pregnancy. Approval in […]
CeQur announces extended wear time, added dosing for mealtime insulin patch pump
CeQur announced today that it picked up two recent FDA clearances for its Simplicity mealtime insulin patch pump system. The FDA cleared Simplicity for an extended wear time of up to seven days and gave the green light to a new 1-unit (1U) device. Additionally, Horw, Switzerland-based CeQur plans to share two clinical posters at […]
PharmaSens enrolls first patient in feasibility study for all-in-one automated insulin patch pump
PharmaSens said today that it enrolled the first patient in a clinical feasibility study of its all-in-one automated insulin patch pump system. The all-in-one pump pairs the Niaa insulin patch pump with a continuous glucose monitor (CGM) made by SiBionics. The companies announced a collaboration aimed at developing the all-in-one solution last year. Their all-in-one wearable […]
Advanced NanoTherapies raises $31M for drug-coated balloon tech
Advanced NanoTherapies announced that it closed an oversubscribed Series B financing worth more than $31 million. An undisclosed strategic investor, along with S3 Ventures, co-led the round. The T45 Fund and new and existing investors also participated. Funding adds to $4 million raised in 2023. The funds support the company’s therapies for coronary and peripheral […]
